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ABSTRACT
Tumor cell contamination might induce relapse after autologous transplantation in breast cancer patients. We
used an ex vivo purging strategy to decrease the number of contaminating breast tumor cells in leukaphereses
without altering the engraftment potential of the hemopoietic progenitor cells. This method is based on
immunoselection of CD34 cells derived from mobilized peripheral blood of patients with metastatic breast
cancer and expansion in the presence of flt3 ligand, stem cell factor, interleukin 6, and thrombopoietin. Tumor
contamination before and after culture was monitored by mammaglobin messenger RNA amplification by
quantitative polymerase chain reaction. We analyzed both adherent and suspended cells obtained after 2 weeks
of culture. Hemopoietic progenitors were increased among suspended cells. In this fraction, tumor cell
contamination was decreased, whereas it increased within the adherent cell fraction. Experimental models
using CD34 cells from healthy donors spiked with breast cancer cells were also constructed to investigate
whether treatment with anti–ErbB-receptor drugs could further reduce the tumor load without affecting the
clonogenic potential of hemopoietic cells. For this purpose, we successfully assayed trastuzumab, a monoclonal
antibody against ErbB-2, and gefitinib, an epidermal growth factor receptor tyrosine kinase receptor inhibitor.
These results suggest that positively selected CD34 cells from cancer patients contain tumor cells and that ex vivo
expansion can reduce the tumor load of the suspended fraction. Target-based agents against ErbB-2, epidermal
growth factor receptor, or both—such as trastuzumab or gefitinib—might increase the efficiency of purging.
© 2006 American Society for Blood and Marrow Transplantation
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The clinical beneﬁt of high-dose chemotherapy
rograms with autologous stem cell transplantation
or the treatment of metastatic breast cancer is a mat-
er of discussion [1,2]. Studies on the prognostic sig-
iﬁcance of occult tumor cell contamination in
pheresis products show contradictory results and are
till not conclusive [3-10].
Gene-marking studies have shown that in pa-
ients with acute or chronic myelogenous leukemia
nd neuroblastoma, tumor cell reinfusion contrib-
tes to relapses after autologous transplantation
11,12]. Contaminating breast cancer cells in leuka- (
8heresis products might be the origin of tumor
elapse. Purging of tumor cells from leukaphereses
ay contribute to increased patient survival. In vitro
tudies showed that tumor cells in mobilized periph-
ral blood (MPB) collections are viable and retain
lonogenic potential [13-16]. Ex vivo expansion of
rogenitor cells might produce a passive elimination
f contaminating tumor cells [17]. Recently, we
howed that the culture conditions that allow exten-
ive self-maintenance of cord blood–derived hemo-
oietic progenitors [18] can be extended to MPB in
he presence of ﬂt3 ligand (FL), stem cell factor
SCF), thrombopoietin (TPO),interleukin (IL)–6, and
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Breast Cancer Cell Purging
Berum. Under such culture conditions, transplantable
recursor and stem cells still retain their proliferation
nd multilineage differentiation capacity [19].
ErbB-2 and epidermal growth factor receptor
EGFR) are expressed in human breast carcinoma
20,21]; they represent ideal targets of anti-ErbB ther-
pies. The humanized anti–ErbB-2 monoclonal anti-
ody trastuzumab has been approved for the treat-
ent of metastatic breast cancer [22-25]. Similarly, the
GFR tyrosine kinase inhibitor geﬁtinib (ZR1839) is
urrently in phase III clinical studies [26-29].
In this work, we set up a small-scale culture system
f MPB from breast cancer patients to obtain the
xpansion of hemopoietic progenitors and the selec-
ive elimination of contaminating tumor cells by tar-
eting ErbB receptors. Because mammaglobin
MAM) is the most speciﬁc marker for the detection of
pithelial cell contamination in hematologic samples
10,30], we used MAM messenger RNA (mRNA) am-
liﬁcation by quantitative polymerase chain reaction
PCR) to monitor tumor contamination before and
fter culture.
ATERIALS AND METHODS
eagents and Recombinant Human Cytokines
Trastuzumab (Herceptin) was obtained from Ge-
entech Inc. (San Francisco, CA). ZD1839 (geﬁtinib)
as kindly provided by AstraZeneca (Macclesﬁeld,
K). Recombinant human (rh) SCF was a generous
ift from Amgen (Thousand Oaks, CA), rhIL-3 was
btained from Novartis (Basel, Switzerland), rhIL-6
as obtained from PeproTech (Rocky Hill, NJ),
h-erythropoietin (Eprex) was obtained from Cilag
Milan, Italy), rhFL was kindly provided by S.D. Ly-
an (Immunex Corp., Seattle, WA), and rhTPO was
generous gift from Kirin Brewery (Tokyo, Japan).
atients and Samples
We studied samples from 10 patients with meta-
tatic breast cancer. Informed consent was obtained
rom all patients according to the institutional guide-
ines. Patients were evaluated for secondary metastatic
esions by means of chest and abdomen computed
omography and bone scintigraphy.
The characteristics of breast cancer patients are
ummarized in Table 1. All patients were female.
PB collections from patients with metastatic breast
ancer and MPB collections from healthy donors were
arvested from the leftovers of leukapheresis proce-
ures. In breast cancer patients, peripheral blood stem
ells were collected after recovery from the third
ourse of conventional-dose chemotherapy with pac-
itaxel (Taxol; Bristol-Myers Squibb, Rome, Italy) 175
g/m2 and vinorelbine (Navelbine; Pierre Fabre,
ome, Italy) 30 mg/m2. Human recombinant granu- c
B&MTocyte colony-stimulating factor (Granocyte 34; Aven-
is Pharma, Milan, Italy) 10 g/kg was administered
rom day5 until the completion of stem cell harvest.
ealthy donors had received only granulocyte colony-
timulating factor for 5 consecutive days. For the
econstitution experiments of tumor contamination,
2 MPB samples derived from healthy donors were
ollected after informed consent was given.
ell Lines
The SKBR3 human breast cancer cell line was
outinely maintained in Dulbecco modiﬁed Eagle me-
ium (Invitrogen Life Technologies, Gaithersburg,
D) with 10% fetal calf serum (Hyclone, Logan,
T). We selected this cell line on the basis of MAM
xpression [30], ErbB-2 genomic ampliﬁcation, and
GFR overexpression [31].
xperimental Contamination Assay
To set up the contamination model, we performed
reconstitution experiment by using peripheral blood
ononuclear cells derived from healthy donors spiked
ith SKBR3 in limiting dilutions from 1 SKBR3 cell
n 10 mononuclear cells to 1 SKBR3 cell in 106 mono-
uclear cells. We used this experimental model to
stablish the degree of tumor contamination of leuka-
hereses from patients.
urification of CD34 Cells
CD34 cells were isolated from MPB mononu-
lear cells with a superparamagnetic microbead selec-
ion system by using a high-gradient magnetic ﬁeld
nd MiniMACS column (Miltenyi Biotec, Bergisch
ladbach, Germany) according to the manufacturer’s
nstructions. Puriﬁcation efﬁciency was veriﬁed by
ow cytometry counterstaining with a CD34 phyco-
rythrin (Becton Dickinson, San Jose, CA) antibody.
n the cell fraction containing puriﬁed cells, the per-
able 1. Characteristics of Enrolled Breast Cancer Patients
Patient No. Age (y) Visceral Metastases Bone Metastases
1 30 Liver No
2 42 Lung No
3 51 Pleural No
4 44 Lymph nodes No
5 53 Lung No
6 56 Liver No
7 49 Liver No
8 37 Lymph nodes, liver No
9 58 Lung, pleural No
10 50 Lung No
atients were evaluated for secondary metastases by means of chest
and abdomen computed tomography and bone scintigraphy.entage of CD34 cells ranged from 90% to 98%.
69
Cc
m
1
T
n
c
I
t
w
w
t
w
Z
a
e
a
C
H
m
i
2
d
S
o
m
o
L
p
s
o
s
A
p
M
c
B
m
t
T
(
G
G
c
C
p
a
G
5
d
C
P
w
S
p
s
S
T
n
w
t
c
w
R
E
M
B
c
5
t
C
i
s
c
f
L
s
w
p
c
o
b
T
P
1
2
3
4
5
m
A
F. Leone et al.
7ell Culture Expansion System
Expansion culture was performed in 24-well tissue
ulture plates with 5  105 CD34 cells per well in 1
L of Iscove modiﬁed Dulbecco medium containing
0% calf serum plus SCF (50 ng/mL), FL (50 ng/mL),
PO (10 ng/mL), and IL-6 (10 ng/mL). Total cell
umber, CD34 cell production, colony-forming
ells (CFC), long-term culture-initiating cell (LTC-
C) content, and tumor cell presence were evaluated at
he start of culture and after 2 weeks.
To reproduce tumor-contaminated leukapheresis,
e performed coculture by spiking 100 SKBR3 cell
ith 106 CD34 cells derived from healthy donors in
he presence of the same growth factors and cultured
ith or without 30 g/mL trastuzumab or 2 mol/L
R1839 (geﬁtinib). Fresh antibody and inhibitor were
dded every 72 hours; growth factors were added
very week. After 2 weeks of culture, the cells were
nalyzed for total cell number, CFC, LTC-IC,
D34, and tumor cell content.
emopoietic Cell Assay
Assays for multilineage granulocyte-macrophage
egakaryocyte colony-forming units were performed
n plasma clots, as previously described [19]. Brieﬂy,
 103 CD34 cells were seeded in plasma clots (4
ishes per point) in the presence of IL-3 (20 ng/mL),
CF (50 ng/mL), and erythropoietin (3 U/mL). Col-
ny scoring was performed on day 14 with an optical
icroscope at 4 magnitude by counting all the col-
nies (50 cells) grown in the plate.
ong-Term Culture-Initiating Cells
The LTC-IC content of unmanipulated and ex-
anded CD34 cells was analyzed as previously de-
cribed [19]. Brieﬂy, 2 103 CD34 cells were seeded
nto a pre-established irradiated human bone marrow
tromal layer and maintained at 37°C for 6 weeks.
fter the culture period, all cells were harvested and
lated for CFC quantitation.
AM Real-Time Quantitative PCR
The detection of tumor contamination of MPB
ollection has been described in detail previously [30].
rieﬂy, total RNA was used as a template for comple-
entary DNA synthesis, and MAM real-time quanti-
ative PCR was performed with speciﬁc primers and
aqMan probes (Perkin Elmer, Foster City, CA)
MAM forward primer, 5=-CAGCGGCTTCCTT-
ATCCT-3=; MAM reverse primer, 5=-TCATG-
TGAGGCTGCTGCT-3=; MAM detection probe,
arboxyﬂuorescein-5=-CCACCCGCGACTGAACAC-
GA-3=-tetramethylrhodamine). The glyceraldehyde
hosphate dehydrogenase (GAPDH) gene was ampliﬁed
s a control (forward GAPDH primer, 5=-GAAGGT-
0AAGGTCGGAGTC-3=; reverse GAPDH primer,
=-GAAGATGGTGATGGGATTTC-3=; GAPDH
etection probe, carboxyﬂuorescein-5=-CAAGCTTC-
CGTTCTCAGCC-3=-tetramethylrhodamine). All
CR reactions were performed in triplicate in a 96-
ell microtiter plate format on an ABI PRISM 7700
equence Detector System (Perkin Elmer), and am-
liﬁcation curves were analyzed as previously de-
cribed [30].
tatistical Analysis
Each CFC assay was performed in quadruplicate.
he results were analyzed by using the Mann-Whit-
ey U nonparametric test. All P values are 2 tailed,
ith signiﬁcance set at P  .05. -Fold increases of
otal cells, CD34 cells, CFCs, and LTC-ICs were
alculated, and their means and standard deviations
ere analyzed.
ESULTS
x Vivo Expansion of Purified CD34 Cells from
PB Derived from Patients with Metastatic
reast Cancer
We veriﬁed the ex vivo expansion potential of our
ulture system on puriﬁed CD34 cells derived from
patients with metastatic breast cancer. We analyzed
he total cell number, CD34 cell production, and
FC and LTC-IC output after 2 weeks of expansion
n the presence of FL, TPO, SCF, and IL-6. Table 2
hows the relative -fold increases of each parameter.
After 2 weeks of culture, total cells and CD34
ells were expanded 40.8  9.2-fold and 4.2  1.8-
old, respectively. CFCs (12.9  4.0-fold) and
TC-IC (8.7  5.0-fold) were also expanded in all
amples. These results were similar to those obtained
ith CD34 cells derived from healthy donors, as
reviously demonstrated [19], thus suggesting that
hemotherapy does not affect the clonogenic capacity
f hemopoietic stem cells in patients with metastatic
reast cancer.
able 2. Expansion Potential of MPB CD34 Cells Derived from
atients with Metastatic Breast Cancer
Patient No.
Fold Increase
Total Cells CD34 Cells CFC LTC-IC
28.2 5.5 9.8 1.8
38.5 2.4 17.8 6.2
50.9 2.3 9.4 12.9
37.6 6.2 10.8 8.5
48.8 4.9 16.9 14
ean  SD 40.8  9.2 4.2  1.8 12.9  4.0 8.7  5.0
total of 5  105 CD34 cells from 5 leukaphereses were cultured
as described in “Materials and Methods.” The fold increase of
total cells, CD34 cells, CFC, and LTC-IC was evaluated after
2 weeks of expansion.
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Breast Cancer Cell Purging
Betection of Tumor Cell Contamination in
nmanipulated and Expanded Leukapheresis
ollections Derived from Patients with Metastatic
reast Cancer
We assessed the presence of tumor contamination
n mononuclear cells derived from 10 leukaphereses
f patients with metastatic breast cancer (Table 1) by
AM quantitative RT-PCR. Five of 10 samples were
ositive for MAM mRNA. To evaluate the degree of
umor contamination, we compared the MAM ampli-
cation curves of positive samples with those obtained
n reconstitution experiments with SKBR3 cells and
eripheral mononuclear cells from healthy donors.
he levels of contamination of leukaphereses from
atients were comparable to those obtained in the
igure 1. Quantitation of tumor contamination on MPB harvest.
ammaglobin ampliﬁcation curves on reconstitution experiments
ith SKBR3 cells and peripheral mononuclear cells (curves from 1
KBR3/10 mononuclear cells to 1 SKBR3/106 mononuclear cells
rom a healthy donor) and on 5 (from patient 1 to patient 5) MPB
ollections derived from breast cancer patients are shown. NTC
ndicates no template control. RN indicates reporter ﬂuorescence
ormalized to internal control.
able 3. Relative Amounts of MAM mRNA in MPB from Breast Can
alibration Curve
Sample*
Calibration
Curve†
Before CD34
Selection
A
1 1.25
2 9.87
3 2.67
4 0.71
5 1.86
alibration
1:106 1
10:106 4.8
100:106 90
D indicates not detectable.
A total of 106 cells collected after each step of manipulation were
Calibration curve was obtained from 1  106 normal mononuclear cells
B&MTimiting dilution ranging from 1 SKBR3 cell in 106 to
SKBR3 in 105 mononuclear cells of healthy donors
Figure 1).
Leukaphereses from patients were subjected to
D34 cell puriﬁcation and cultured. After 2 weeks of
xpansion, the levels of MAM mRNA were compared
ith those of unmanipulated mononuclear cells and
ith those of puriﬁed CD34. After CD34 selection,
ur system was unable to detect any level of MAM;
his suggests that the tumor load was reduced below
he threshold level of detection. During cell culture, 2
ifferent fractions are distinguished: a nonadherent
ubpopulation, which consists of hemopoietic cells
hat grow in suspension, and adherent cells containing
pithelial tumor cells, monocytes, and endothelial
ells. The level of MAM mRNA in these 2 cultured
ubpopulations was compared with that of unmanipu-
ated mononuclear cells. Tumor marker was increased
n the adherent fraction of culture compared with
nmanipulated mononuclear cells, thus suggesting
hat our system expands, also contaminating epithelial
umor cells. Conversely, MAM mRNA was reduced in
he suspended fraction in all samples. In 1 sample,
umor cells became undetectable. Table 3 shows the
elative amounts of MAM mRNA in each sample
from patient 1 to patient 5) after each step of in vitro
anipulation compared with those of a standard cal-
bration curve with SKBR3 and mononuclear cells
rom healthy donors.
ffect of Trastuzumab and Gefitinib on Tumor
ells in Coculture
It has been demonstrated that trastuzumab, a
onoclonal antibody directed against ErbB-2, inhibits
he proliferation of ErbB-2–overexpressing cells [22-
5,32]. Similarly, ZD1839, a tyrosine kinase inhibitor
peciﬁc for EGFR, is able to block the growth of
GFR-expressing human cancer cells [26-29]. We
nalyzed whether these 2 molecules might contribute
ients (from Patient 1 to Patient 5) Compared with Those of the
D34
ion
Adherent Fraction
After Expansion
Nonadherent Fraction
After Expansion
2.51 0.53
58.26 1.55
4.16 ND
8.56 0.4
4.47 0.09
ed to MAM real-time quantitative PCR.cer Pat
fter C
Select
ND
ND
ND
ND
ND
subject
spiked with increasing numbers of SKBR3 (1, 10, and 100).
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7o purge contaminated stem cell collections during in
itro manipulation.
We performed coculture with CD34 cells ob-
ained by leukaphereses from healthy donors and the
KBR3 cell line in the presence or absence of trastu-
umab or geﬁtinib. This cell line was selected for the
haracteristics of ErbB-2 genomic ampliﬁcation and
GFR overexpression, which allow trastuzumab and
eﬁtinib to inhibit cell growth. After 2 weeks of cul-
ure in the presence of trastuzumab, MAM mRNA was
ndetectable in the suspended fraction (data not shown).
elative quantitation with comparative threshold cycle
ethods of the tumor marker (Table 4) demonstrated
hat on adherent fractions, the levels of MAM in the
rastuzumab-treated cells (5.25-fold increase of MAM
ith respect to the start of culture) were lower than
hose in untreated cultures (278.2-fold increase of
AM with respect to the start of culture), which
igure 2. Effect of trastuzumab on cocultures of SKBR3 cells and
emopoietic precursor cells. Representative ampliﬁcation curves are
hown of GAPDH (control gene) and MAM (target gene) obtained
y mammaglobin (MAM) quantitative reverse transcriptase-PCR in
oculture of SKBR3 tumor cells and normal progenitor cells. Cells
ere analyzed before (T0) and after 2 weeks in the presence (T)
r absence (T) of trastuzumab. NTC indicates no template con-
rol. RN indicates reporter ﬂuorescence normalized to internal
able 4. Relative Quantitation of Mammaglobin by Using the Compar
Variable
MAM
Average Ct
GAPDH
Average Ct (MA
KBR3 T0 33.65  0.002 28.66  0.12
KBR3  T 31.23  0.11 28.63  0.44
KBR3  T 25.34  0.46 28.47  0.34
t indicates the threshold cycle, deﬁned as the PCR cycle at which
target-speciﬁc detection signal (Rn) that passes above the base
value from the average MAM Ct value. The calculation of C
given for MAM relative to SKBR3 T0 is determined by evaluat
KBR3 T0 indicates the start of coculture of CD34 cells obtained
KBR3T indicates coculture of CD34 cells obtained from leuka
in the presence of trastuzumab.
KBR3T indicates coculture of CD34 cells obtained from leuka
in the absence of trastuzumab.ontrol.
2resented transcript levels 52.9-fold higher than in the
resence of the antibody. Figure 2 shows MAM and
APDH ampliﬁcation curves obtained after 2 weeks
f coculture in reconstitution assays with SKBR3 cells
nd hemopoietic precursors in the absence or pres-
nce of trastuzumab. The same results were obtained
pon EGFR tyrosine kinase inhibitor treatment.
oreover, by investigating CFC content, we demon-
trated that trastuzumab and geﬁtinib did not change
he clonogenic capacity of hemopoietic cells (Table 5).
ISCUSSION
This work proposes a novel strategy for tumor cell
urging of leukaphereses from patients with meta-
tatic breast cancer scheduled for high-dose chemo-
herapy programs with hemopoietic stem cell rescue.
his system is based on ex vivo expansion of CD34
ells from patients with metastatic breast cancer in
ombination with ErbB receptor targeting.
In our laboratory, we previously set up an efﬁcient
xpansion method of adult CD34 cells derived from
ealthy donors [19]. Here we report that this culture
ondition (FL, TPO, SCF, and IL-6 in the presence
f serum) allows the maintenance and even some ex-
ansion of CD34 derived from tumor cell–positive
t Methods
PDH)
Ct
(Ct DCtSKBR3 T0)
MAM
(Relative to SKBR3 T0)
0 1
2.39 5.25
8.12 278.2
porter ﬂuorescence dye cleaved from the MAM probe generates a
e Ct value is determined by subtracting the average GAPDH Ct
es subtraction by the Ct calibrator value (SKBR3 T0). The range
expression 2DDCt
leukaphereses of healthy donors spiked with SKBR3 cells.
s of healthy donors spiked with SKBR3 cells and grown for 2 weeks
s of healthy donors spiked with SKBR3 cells and grown for 2 weeks
able 5. Colony-Forming Cell (CFC) Content
Variable CFC
Trastuzumab 182 (64–346)
Trastuzumab 147 (52–233)
Gefitinib 122 (70–154)
Gefitinib 136 (78–148)
umor-contaminated leukaphereses were reconstituted by spiking
100 SKBR3 cells with 106 CD34 cells derived from healthy
donors and expanded with or without 30 g/mL trastuzumab
and 2 mol/L ZR1839. After the period of culture, CFC con-
tent was evaluated. Values indicate the median and range of
several experiments (6 experiments with different donors in theative C
Ct
MGA
4.99
2.6
3.13
the re
line. Th
t involv
ing the
from
pherese
pheresepresence of trastuzumab and 5 with geﬁtinib).
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Bollections. The absolute number of CD34 cells and
FC and LTC-IC content were signiﬁcantly in-
reased after 2 weeks of culture. The hemopoietic
xpansion potential in contaminated collections was
ot different from that of healthy donors [19]. None-
heless, tumor cells persist and proliferate in vitro, as
emonstrated by quantitative reverse transcriptase-
CR at the end of the culture period. However, we
bserved differences between the adherent and sus-
ended fractions of culture: the adherent cells con-
ained higher levels of MAM mRNA than unmanipu-
ated cells, whereas on the suspended fraction, which
ontains most hematopoietic progenitors, there was a
eduction of the marker level in all cultured samples.
he ability of tumor epithelial cells to adhere on
lastic could contribute to decreasing the tumor con-
amination. Positive selection of CD34 cells from
PB of breast cancer patients is not enough to com-
letely eliminate epithelial tumor cells in hemopoietic
utografts, and the ex vivo culture condition does not
esult in an effective purging of tumor cells. For these
easons, to improve the efﬁciency of the tumor-purg-
ng protocol, we considered additional strategies, such
s targeting ErbB family receptors during hemopoi-
tic ex vivo expansion. We investigated whether tras-
uzumab, the monoclonal antibody against ErbB-2
22-25,31], and the EGFR tyrosine kinase receptor
nhibitor ZD1839 (geﬁtinib) [26-29] are able to re-
uce the tumor load without affecting the clonogenic
otential of hemopoietic cells.
CD34 cells obtained from leukaphereses of
ealthy donors were mixed with the ErbB-2 and
GFR SKBR3 human breast cancer cell line and
ultured for 2 weeks in the presence of trastuzumab
nd geﬁtinib. After 2 weeks of culture in the presence
f trastuzumab, the tumor marker was undetectable in
uspended cells, and there was a 52.9-fold reduction in
he adherent fraction. Moreover, clonogenic assays
howed that trastuzumab and geﬁtinib spare hemopoi-
tic cells. These results demonstrate that EGFR tar-
eting does not upset the hemopoietic developmental
apacity.
In conclusion, our protocol might be used as an
fﬁcient in vitro purging of leukapheresis collections
rom breast cancer patients with ErbB-2 overexpres-
ion or EGFR expression.
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